Loading...
•
Dec 31, 2021
Ionis Q4 2021 Earnings Report
Ionis Pharmaceuticals reported financial results for the fourth quarter and full year ended December 31, 2021, and recent business achievements.
Key Takeaways
Ionis Pharmaceuticals exceeded its 2021 financial guidance with revenues of $810 million. The company is well capitalized with $2.1 billion in cash and short-term investments at year-end. They are advancing their commercial strategy and go-to-market plans for near-term commercial opportunities.
Ionis exceeded 2021 financial guidance with revenues of more than $800 million.
A collaboration with AstraZeneca was initiated to jointly develop and commercialize eplontersen.
Phase 3 studies with olezarsen in patients with severely high triglycerides and donidalorsen in patients with hereditary angioedema were initiated.
Biogen licensed ION306 (BIIB115) for the treatment of SMA with the potential for extended dosing intervals, resulting in a $60 million payment from Biogen.
Revenue by Segment
Forward Guidance
Ionis provided full year 2022 financial guidance on a non-GAAP basis. They anticipate revenue greater than $575 million, operating expenses between $825 million and $850 million, a net loss less than $275 million, and cash and short-term investments around $1.7 billion.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...